Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Communicable disease control

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Communicable disease control. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-003281-25 Sponsor Protocol Number: ALBIOS STUDY Start Date*: 2008-04-17
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: Efficacy of albumin administration for volume replacement in patients with severe sepsis or septic shock
    Medical condition: Patients with severe sepsis or septic shock
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005604-54 Sponsor Protocol Number: NXL104/2002 Start Date*: 2009-04-10
    Sponsor Name:Novexel, S.A.
    Full Title: A prospective, multicentre, double-blind, randomized, comparative study to estimate the safety, tolerability and efficacy of NXL104/ceftazidime plus metronidazole vs. meropenem in the treatment of ...
    Medical condition: Complicated intra-abdominal infections (cIAI) in hospitalised adults
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021881 Infections and infestations SOC
    9.1 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000476-34 Sponsor Protocol Number: V59_40 Start Date*: 2011-06-08
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase IV,PlaceboControlled,Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix) and Quadrivale...
    Medical condition: Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.1 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000439-42 Sponsor Protocol Number: TAP Start Date*: 2019-12-31
    Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust
    Full Title: The time to protection and adherence requirements of TRUVADA® and DESCOVY® required for protection from HIV-1 infection: bridging the data gaps
    Medical condition: Human Immunodeficiency Viruses
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005421-59 Sponsor Protocol Number: 106388-106390 Start Date*: 2006-03-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, randomized, controlled, multicentre, primary & booster study to demonstrate the non-inferiority of the MenC & Hib immune responses of GSK Biologicals’ Hib-MenC vaccine co-adminis...
    Medical condition: Two-dose primary immunization course in healthy infants in the first year of life with a booster dose at 11 months of age against Haemophilus influenzae type b and meningococcal serogroup C diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000656-99 Sponsor Protocol Number: REMPEX-507 Start Date*: 2023-09-28
    Sponsor Name:Rempex Pharmaceuticals-Melinta Therapeutics
    Full Title: An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE® (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years o...
    Medical condition: Suspected or confirmed negative bacterial infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10021881 - Infections and infestations 10004047 Bacterial infections NEC HLT
    20.1 10021881 - Infections and infestations 10060945 Bacterial infection PT
    20.1 100000004862 10018657 Gram-negative bacterial infection NOS LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-004420-29 Sponsor Protocol Number: 205213 Start Date*: 2016-12-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 2, Open-label, Controlled, Multi-Center Extension Study to Evaluate 4-Year Antibody Persistence and Booster Response Fol-lowing MenABCWY Vaccination in Healthy Adolescents and Young Adults ...
    Medical condition: Healthy volunteers (Immunisation against meningococcal infections)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002938-23 Sponsor Protocol Number: pro-SWAP104622 Start Date*: 2018-02-06
    Sponsor Name:Radboud University Medical Center
    Full Title: The effect of rectal swab culture-guided antimicrobial prophylaxis in men undergoing prostate biopsy on infectious complications and cost of care: A randomized controlled trial in the Netherlands.
    Medical condition: Antimicrobial prophylaxis for patients undergoing prostate biopsy concerning infectious complications.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10042613 - Surgical and medical procedures 10064736 Antibiotic prophylaxis PT
    20.1 10022891 - Investigations 10004857 Biopsy prostate PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004556-71 Sponsor Protocol Number: P05514 Start Date*: 2009-05-25
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: Estudio de un solo grupo para facilitar tratamiento con boceprevir a sujetos con el genotipo 1 del virus de la hepatitis C crónica que no han respondido a peginterferón/ribavirina en estudios previ...
    Medical condition: Hepatitis C Crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 PT
    9.1 10021881 SOC
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019064-36 Sponsor Protocol Number: MA-PY-Hp09-01 Start Date*: 2011-07-17
    Sponsor Name:Axcan Pharma INC
    Full Title: Eficacia y seguridad de PYLERA (subcitrato potásico de bismuto, metronidazol y clorhidrato de tetraciclina) con omeprazol, administrados 10 días en sujetos con fracaso del tratamiento de erradicaci...
    Medical condition: erradicación de Helicobacter pylori
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10019377 Helicobacter pylori infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004760-39 Sponsor Protocol Number: P05685 Start Date*: 2009-04-03
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003020-23 Sponsor Protocol Number: 1615R2132 Start Date*: 2017-11-23
    Sponsor Name:Shionogi B.V.
    Full Title: A Multicenter, Randomized, Double-blind, Parallelgroup, Clinical Study of S-649266 Compared with Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacteria...
    Medical condition: Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) LV (Completed) HU (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004864-38 Sponsor Protocol Number: P05411 Start Date*: 2009-10-02
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    13.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    13.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    13.1 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005508-42 Sponsor Protocol Number: P05216 Start Date*: 2008-08-27
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) IT (Completed) BE (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005151-42 Sponsor Protocol Number: P05101 Start Date*: 2008-08-28
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) IT (Completed) BE (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012782-63 Sponsor Protocol Number: P06086 Start Date*: 2010-01-08
    Sponsor Name:Schering-Plough Research Institution, A Division of Schering Corporation
    Full Title: Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anemia
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    9.1 10019744 PT
    9.1 10021881 SOC
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004483-30 Sponsor Protocol Number: GS-US-236-0115 Start Date*: 2012-01-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) AT (Completed) PT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004963-56 Sponsor Protocol Number: GS-US-236-0121 Start Date*: 2012-01-25
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006280-78 Sponsor Protocol Number: PYLHp07-01 Start Date*: 2008-03-28
    Sponsor Name:Axcan Pharma Inc.
    Full Title: Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omep...
    Medical condition: Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019377 Helicobacter pylori infection LLT
    9.1 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IE (Completed) DE (Completed) NL (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003708-11 Sponsor Protocol Number: GS-US-236-0128 Start Date*: 2012-11-05
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) PT (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 16:31:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA